Suppr超能文献

静脉注射 SOM230 后,在 AR42J 动物肿瘤模型体内未见生长抑素 SST(2)受体内化。

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

机构信息

Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland.

出版信息

Eur J Pharmacol. 2010 Oct 10;644(1-3):257-62. doi: 10.1016/j.ejphar.2010.07.005. Epub 2010 Jul 16.

Abstract

Among clinically relevant somatostatin functions, agonist-induced somatostatin receptor subtype 2 (sst(2)) internalization is a potent mechanism for tumor targeting with sst(2) affine radioligands such as octreotide. Since, as opposed to octreotide, the second generation multi-somatostatin analog SOM230 (pasireotide) exhibits strong functional selectivity, it appeared of interest to evaluate its ability to affect sst(2) internalization in vivo. Rats bearing AR42J tumors endogenously expressing somatostatin sst(2) receptors were injected intravenously with SOM230 or with the [Tyr(3), Thr(8)]-octreotide (TATE) analog; they were euthanized at various time points; tumors and pancreas were analyzed by immunohistochemistry for the cellular localization of somatostatin sst(2) receptors. SOM230-induced sst(2) internalization was also evaluated in vitro by immunofluorescence microscopy in AR42J cells. At difference to the efficient in vivo sst(2) internalization triggered by intravenous [Tyr(3), Thr(8)]-octreotide, intravenous SOM230 did not elicit sst(2) internalization: immunohistochemically stained sst(2) in AR42J tumor cells and pancreatic cells were detectable at the cell surface at 2.5min, 10min, 1h, 6h, or 24h after SOM230 injection while sst(2) were found intracellularly after [Tyr(3), Thr(8)]-octreotide injection. The inability of stimulating sst(2) internalization by SOM230 was confirmed in vitro in AR42J cells by immunofluorescence microscopy. Furthermore, SOM230 was unable to antagonize agonist-induced sst(2) internalization, neither in vivo, nor in vitro. Therefore, SOM230 does not induce sst(2) internalization in vivo or in vitro in AR42J cells and pancreas, at difference to octreotide derivatives with comparable sst(2) binding affinities. These characteristics may point towards different tumor targeting but also to different desensitization properties of clinically applied SOM230.

摘要

在临床上相关的生长抑素功能中,激动剂诱导的生长抑素受体亚型 2(sst(2))内化是一种利用 sst(2)亲和放射性配体(如奥曲肽)进行肿瘤靶向的有效机制。由于与奥曲肽相比,第二代多生长抑素类似物 SOM230(帕瑞肽)表现出强烈的功能选择性,因此评估其在体内影响 sst(2)内化的能力似乎很有趣。用内源性表达生长抑素 sst(2)受体的 AR42J 肿瘤的大鼠静脉注射 SOM230 或[Tyr(3), Thr(8)]-奥曲肽(TATE)类似物;在不同时间点处死大鼠;用免疫组织化学法分析肿瘤和胰腺中生长抑素 sst(2)受体的细胞定位。还通过 AR42J 细胞中的免疫荧光显微镜评估 SOM230 诱导的 sst(2)内化。与静脉内[Tyr(3), Thr(8)]-奥曲肽引发的有效体内 sst(2)内化不同,静脉内 SOM230 不会引发 sst(2)内化:在 SOM230 注射后 2.5min、10min、1h、6h 或 24h,可在 AR42J 肿瘤细胞和胰腺细胞的免疫组织化学染色 sst(2)在细胞表面检测到,而在用[Tyr(3), Thr(8)]-奥曲肽注射后则发现 sst(2)在细胞内。通过 AR42J 细胞中的免疫荧光显微镜,在体外证实了 SOM230 刺激 sst(2)内化的能力。此外,SOM230 既不能在体内,也不能在体外拮抗激动剂诱导的 sst(2)内化。因此,与具有可比 sst(2)结合亲和力的奥曲肽衍生物不同,SOM230 不会在体内或体外的 AR42J 细胞和胰腺中诱导 sst(2)内化。这些特征可能指向不同的肿瘤靶向,但也指向临床应用的 SOM230 具有不同的脱敏特性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验